The Situation

The gap between scientific innovation and commercial viability is one of the most studied problems in economic development — and one of the least solved. Billions of dollars flow into research institutions every year. Patents are filed. Discoveries are made. And a significant portion of those discoveries never become products, companies, or jobs.

The standard explanation is funding. But funding is rarely the first problem. The first problem is almost always communication — or more precisely, a failure of translation between the mentality that produces innovation and the mentality that commercializes it.

I’ve observed this failure from the inside of a diagnostic startup, from the floor of one of the world’s largest life science conferences, and from six months of deliberate engagement with the Knoxville and Tennessee innovation ecosystem. The pattern is consistent: technical and regulatory environments communicate in a data-forward style. Investors, buyers, and commercial partners think in a narrative-forward style. When those two mentalities meet without a translation layer, confusion compounds at every handoff — and promising innovations stall.

The gap isn’t between smart people and dumb investors. It’s between mentalities. Data-forward and narrative-forward thinking require a bridge — and most ecosystems don’t have one.

The Challenge

Founders and researchers almost always get hung up on the evidence that their product works: the data, the methodology, the science. They get stuck inside what they’re building. When they try to communicate to buyers and investors, they lead with proof rather than connecting the other party to the implications of what they’ve built.

But investors and commercial buyers aren’t asking ‘Does this work?’ They’re asking ‘If this works, what changes — and for whom?’ The founder who leads with proof is answering a question the investor isn’t asking yet. The investor is waiting to hear why they should care enough to want the proof.

This isn’t a skills problem. It’s a structural one. Researchers are rewarded throughout their careers for rigor, precision, and methodological defensibility. Those are exactly the wrong instincts for a first conversation with a partner or investor. Fixing it requires more than coaching individual founders. It requires an ecosystem that builds the translation layer into how innovations move from institution to market.

Founders think their job is to prove the innovation is real. Investors are waiting to hear why they should care enough to want the proof. Sequence is everything.

The Approach

A healthy innovation ecosystem doesn’t just aggregate resources — it puts them in conversation. Research institutes, commercialization pathways, investors, incubators, accelerators, and business infrastructure each serve a distinct function. What makes an ecosystem work is the connective tissue between those functions: the organizations and people who understand what each party needs and can move value between them in cycles that benefit multiple parties simultaneously.

What it feels like to be a startup founder inside a functioning ecosystem is to have a vast array of resources, mentors, and feedback mechanisms surrounding you. Organizations come together to accelerate your progress. What it feels like to be outside one is to sit alone trying to figure out, one question at a time, things that are far outside your expertise as an innovator.

Knoxville has the assets for a world-class innovation ecosystem: Oak Ridge National Laboratories, the University of Tennessee, TVA, a research park, and a warm entrepreneurial community. The gap is structural, not substantive. Each institution has historically operated within its own resources and motivations, leaving the connective work undone. What changes the trajectory isn’t more assets — it’s a cohesive organizing function that pulls those assets into a coordinated commercialization pathway.

Results

This framework was developed through direct observation across two regional ecosystems (Knoxville and Nashville), experience as a fractional CMO serving early-stage diagnostics and biotech companies, and three years inside a startup navigating merger, product launch, capital raise, and national scale-up. The observations are grounded in practice, not theory.

2 regional ecosystems observed from the inside: Knoxville/Oak Ridge and Nashville — with direct experience of both the warmth of Knoxville’s entrepreneurial community and the complexity of its research-to-market infrastructure

3+ years inside a diagnostic startup doing the translation work at every commercialization inflection point

100+ investor meetings informed by iterative learning about what capital actually needs to see — not just a good story, but a defensible addressable market

The most important finding: the accessible market question — not total market size, but the specific, reachable slice given regulatory status and reimbursement constraints — is the question investors keep pushing on and founders consistently underprepare for.

Taking Knoxville from a place where many innovations happen to a place where many innovations go to market requires a cohesive organizing function — not more assets, but better connective tissue between the ones already here.

Why This Work Transfers

The translation gap between research and commercialization is not unique to diagnostics or to Knoxville. Any region with strong research institutions — and the economic development aspiration to turn that research into companies and jobs — faces the same structural challenge. The assets exist. The intent exists. What’s missing is the function that bridges the two.

What this framework demonstrates is a way of thinking about that function systematically: identify where the mentalities diverge, build the bridge at the point of divergence, and measure success not by the number of introductions made but by whether value actually moved. The discipline is the same whether you’re helping a single founder prepare for an investor meeting or designing the programming for a regional innovation council.

The through-line is facilitated exchange — creating the conditions for resources, information, and capital to move between parties with different needs in cycles that sustain the whole system. That’s what a fractional CMO does for a diagnostic company. It’s what a Director of Innovation does for a region. The scale changes. The function doesn’t.